Trials / Withdrawn
WithdrawnNCT02878863
Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis
Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Treatment of Auto-immune Hepatitis
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Xiaoli Fan · Academic / Other
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
An open-label,prospective, randomized pilot study to evaluate the efficacy, safety and tolerability of paeoniflorin, for the treatment of autoimmune hepatitis (AIH) with mild necroinflammatory activity on liver biopsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paeoniflorin + phosphatidylcholine or silymarin | |
| DRUG | Phosphatidylcholine or silymarin |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2017-03-01
- Completion
- 2017-07-01
- First posted
- 2016-08-25
- Last updated
- 2017-07-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02878863. Inclusion in this directory is not an endorsement.